THRB and metabolic dysfunction-associated steatohepatitis: The MAESTRO-NASH trial, a rigorous global phase 3 study, demonstrated that resmetirom alleviates hepatic steatosis, inflammation, and fibrosis through thyroid hormone receptor-β (THR-β) agonism—a novel mechanism distinct from previously unsuccessful candidates.